97607-60-8

Upstream product

• 100-55-0 3-hydroxymethylpyridin 
• 36016-39-4 N-(tert-butoxycarbonyl)-O-(mesitylsulfonyl)hydroxylamine 
• 36016-40-7 mesitylenesulfonylhydroxylamine 

Downstream Products

• 1069070-77-4 pyrazolo[1,5-a]pyridine-2,4-dicarboxylic acid 2-ethyl ester 
• 85364-60-9 methyl 6-hydroxymethyl-2-phenylpyrazolo<1,5-a>pyridine-3-carboxylate 
• 97607-71-1 methyl 4-hydroxymethyl-2-phenylpyrazolo<1,5-a>pyridine-3-carboxylate 
• 85364-59-6 4-methyl-2-phenylpyrazolo<1,5-a>pyridine 

Relevant academic research and scientific papers

N-CYCLOBUTYL-IMIDAZOPYRIDINE OR -PYRAZOLOPYRIDINE CARBOXAMIDES AS TRPV1 ANTAGONISTS

A compound of formula (I) wherein X1 represents a hydrogen atom, or a CH2OH group X2 represents a hydrogen atom, a fluorine atom, an OCH3 group or a CH2OH group, and at least one of X1 and

Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast

Ibudilast [1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)-2-methylpropan-1-one] is a nonselective phosphodiesterase inhibitor used clinically to treat asthma. Efforts to selectively develop the PDE3- and PDE4-inhibitory activity of ibudilast led to replacemen

PYRAZOLOPYRIDINE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

A novel pyrazolopyridine derivative is provided which is useful as a pharmaceutical drug having phosphodiesterase inhibitory activity. The pyrazolopyridine derivative is represented by the following general formula (1): [wherein R1 is a hydroge

PYRAZOLOPYRIDINE CARBOXAMIDE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR COMPRISING THE DERIVATIVE

A novel pyrazolopyridine carboxamide derivative is provided that is useful as a pharmaceutical drug having phosphodiesterase inhibitory activity. The pyrazolopyridine carboxamide derivative is represented by the following general formula (1): (Example: 2-

Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient

Novel pyrazolopyridine-4-yl pyridazinone derivatives serve as phosphodiesterase inhibitors and are useful compounds for use in pharmaceutical products. Specifically, the compounds of the present invention are pyrazolopyridine-4-yl pyridazinone derivatives represented by the following general formula (1): (Example: 6-(2-ethyl-7-methoxy-pyrazolo[1,5-a]pyridine-4-yl)-5-methyl-4, 5-dihydro-3(2H)-pyridazinone).

HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS

Heteroaryl amide analogues are provided, of Formula (I), wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of con

Selective dopamine D-2 autoreceptor agonists with 8-azaindole substructure: Synthesis and theoretical investigations

Starting from the 1,3-dipolar cycloaddition product 6a the peri-fused β-ketoester 7 is prepared. 7 is employed as a key intermediate for the synthesis of the D-2 autoreceptor agonist 5. Two alternative approaches are used for installing the amino function

Synthesis of Peri-fused Indolizines and Azaindolizines by Intramolecular 1,3-Dipolar Cycloaddition of 3-(Phenylpropynoyloxyalkyl)pyridine N-Ylides

Treatment of 3-(phenylpropynoyloxymethyl)-N-aminopyridium salt with potassium carbonate in methanol gave unexpectedly 4-methyl-2-phenylpyrazolopyridine and methyl 6- and 4-hydroxymethyl-2-phenylpyrazolopyridine-3-carboxylates.Similar treatme